Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lacerda, Renata B ^a   da Silva, Leandro L ^a   de Lima, Cleverton K F ^a   Miguez, Eduardo ^a   Miranda, Ana Luisa P ^a   Laufer, Stefan A ^b   Barreiro, Eliezer J ^a   Fraga, Carlos A M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' (4 CHLOROBENZYLIDENE)ACETOHYDRAZIDE; 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' (4 HYDROXYBENZYLIDENE)ACETOHYDRAZIDE; 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' (PROPAN 2 YLIDENE)ACETOHYDRAZIDE; 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' [(4 HYDROXYNAPHTHALEN 1 YL)METHYLENE]ACETOHYDRAZIDE; 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' [4 (2 MORPHOLINOETHOXY)BENZYLIDENE]ACETOHYDRAZIDE; 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N' [[4 (2 MORPHOLINOETHOXY)NAPHTHALEN 1 YL]METHYLENE]ACETOHYDRAZIDE; 2 [(3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5YL)(METHYL)AMINO]ACETOHYDRAZIDE; 3 TERT BUTYL N METHYL 1 PHENYL 1H PYRAZOL 5 AMINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIINFLAMMATORY AGENT; ETHYL 2 [(3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5YL)(METHYL)AMINO]ACETATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YL) N METHYLACETAMIDE; N PHENYLPYRAZOLYL N GLYCINYLHYDRAZONE DERIVATIVE; N' BENZYLIDENE 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YL)ACETAMIDE; N' BENZYLIDENE 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO) N METHYLACETOHYDRAZIDE; N' BENZYLIDENE 2 (3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5 YLAMINO)ACETOHYDRAZIDE; N' BENZYLIDENE 2 [(3 TERT BUTYL 1 PHENYL 1H PYRAZOL 5YL)(METHYL)AMINO]ACETOHYDRAZIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; DRUG DEGRADATION; DRUG DESIGN; DRUG OXIDATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MACROPHAGE; MOLECULAR WEIGHT; MOUSE; NOCICEPTION; NONHUMAN; PH; RAT; STRUCTURE ACTIVITY RELATION; THERMAL HYPERNOCICEPTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG DESIGN; FEMALE; HYDRAZONES; MALE; MICE; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; RATS; TUMOR NECROSIS FACTOR-ALPHA; UREA;

EID: 84867325690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046925     Document Type: Article

References (24)

1. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H, (2011) Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 7: 33-42.
2. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, et al. (2008) Cytokines and anticytokines in psoriasis. Clin Chim Acta 394: 7-21.
3. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, et al. (2005) Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 166: 637-644.
4. Moller DE, (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11: 212-217.
5. Locksley RM, Killeen N, Lenardo MJ, (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104: 487-501.
6. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, et al. (2004) Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200: 367-376.
7. Lin J, Ziring D, Desai S, Kim S, Wong M, et al. (2008) TNF alpha blockade in human diseases: An overview of efficacy and safety. Clin Immunol 126: 13-30.
8. Tayal V, Kalra BS, (2008) Cytokines and anti-cytokines as therapeutics- An update. Eur J Pharmacol 579: 1-12.
9. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL, (2003) Anti-TNF-alpha therapies: The next generation. Nat Rev Drug Discovery 2: 736-746.
10. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2482-2482.
11. Lee JC, Griswold DE, Votta B, Hanna N, (1988) Inhibition of monocyte-Il-1 production by the anti-inflammatory compound SKF-86002. Int J Immunopharmacol 10: 835-843.
12. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, et al. (1994) A protein-kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
13. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, et al. (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37: 13846-13853.
14. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268-272.
15. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, et al. (2002) Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem 45: 2994-3008.
16. Duarte CD, Barreiro EJ, Fraga CAM, (2007) Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 7: 1108-1119.
17. Palla G, Predieri G, Domiano P, Vignali C, Turner W, (1986) Conformational behavior and E/Z isomerization of N-acyl and N-aroylhydrazones. Tetrahedron 42: 3649-3654.
18. Wyrzykiewicz E, Blaszczyk A, (2000) New isomeric N-substituted hydrazones of 2-, 3-and 4-pyridinecarboxaldehydes and methyl-3-pyridylketone. J Heterocyclic Chem 37: 975-981.
19. Peng YY, Liu HL, Tang M, Cai LS, Pike V, (2009) Highly efficient N-monomethylation of primary aryl amines. Chin J Chem 27: 1339-1344.
20. Kummerle AE, Raimundo JM, Leal CM, da Silva GS, Balliano TL, et al. (2009) Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. Eur J Med Chem 44: 4004-4009.
21. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, et al. (1997) Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283: 918-924.
22. Mosmann T, (1983) Rapid colorimetric assay for cellula growth and survival- Application to proliferation and cyto-toxicity assays. J Immunol Methods 65: 55-63.
23. Goettert M, Graeser R, Laufer SA, (2010) Optimization of a nonradioactive immunosorbent assay for p38 alpha mitogen-activated protein kinase activity. Anal Biochem 406: 233-234.
24. Lavich TR, Cordeiro RSB, Silva PMR, Martins MA, (2005) A novel hot-plate test sensitive to hyperalgesic stimuli and non-opioid analgesics. Braz J Med Biol Res 38: 445-451.